The estimated Net Worth of Barry E Greene is at least $9.47 millió dollars as of 10 November 2022. Mr. Greene owns over 14,500 units of Karyopharm Therapeutics Inc stock worth over $34,736 and over the last 20 years he sold KPTI stock worth over $9,249,244. In addition, he makes $189,573 as Lead Independent Director at Karyopharm Therapeutics Inc.
Barry has made over 43 trades of the Karyopharm Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 14,500 units of KPTI stock worth $499,960 on 10 November 2022.
The largest trade he's ever made was exercising 88,659 units of Karyopharm Therapeutics Inc stock on 20 September 2017 worth over $2,556,926. On average, Barry trades about 8,015 units every 60 days since 2004. As of 10 November 2022 he still owns at least 46,940 units of Karyopharm Therapeutics Inc stock.
You can see the complete history of Mr. Greene stock trades at the bottom of the page.
Barry E. Greene serves as Lead Independent Director of the Company. Mr. Greene has served as a member of our Board since January 2013 and as our Lead Independent Director since January 2015. Mr. Greene has served as President of Alnylam Pharmaceuticals, Inc., a public biopharmaceutical company, since 2007, and served as its Chief Operating Officer from 2003 to September 2016. Mr. Greene joined Alnylam in 2003, bringing over 15 years of experience in the healthcare and consulting industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., a public biopharmaceutical company, where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration, or the FDA, approval and launch of VELCADE ® (bortezomib) in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Prior to Mediconsult.com, Mr. Greene’s experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), a public biopharmaceutical company; Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting, a consulting company, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene has served as a member of the board of directors of Acorda Therapeutics, Inc., a public biopharmaceutical company, since 2007, where he also serves as a member of its compensation committee. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.
As the Lead Independent Director of Karyopharm Therapeutics Inc, the total compensation of Barry Greene at Karyopharm Therapeutics Inc is $189,573. There are 10 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.
Barry Greene is 56, he's been the Lead Independent Director of Karyopharm Therapeutics Inc since 2015. There are 8 older and 14 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.
Barry's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic... és Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include: